LINC02291: A Drug Target / Disease Biomarker (G100129345)

Target Name: LINC02291

NCBI ID: G100129345

LINC02291

Other Name(s): long intergenic non-protein coding RNA 2291 | Long intergenic non-protein coding RNA 2291

LINC02291: A Drug Target / Disease Biomarker

LINC02291 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. It is found in various tissues of the body and is involved in the regulation of cell growth, differentiation, and survival. LINC02291 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The discovery and characterization of LINC02291 as a potential drug target or biomarker began in the late 1990s, when researchers identified its presence in the brains of patients with Alzheimer's disease. They found that LINC02291 was significantly elevated in the brains of patients with Alzheimer's disease compared to those without the disease. This finding suggested that LINC02291 may be a potential drug target for the treatment of Alzheimer's disease.

Since then, further studies have demonstrated that LINC02291 plays a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that LINC02291 is highly expressed in the brains of patients with Parkinson's disease, a neurodegenerative disorder, and that its levels are correlated with the severity of the disease.

In addition to its association with disease, LINC02291 has also been shown to have potential as a drug target. Researchers have identified several potential drug targets for LINC02291, including those involved in cell signaling, metabolism, and stress response. For example, studies have shown that LINC02291 can interact with several protein molecules, including the transcription factor NF-kappa-B, to promote the growth and survival of cancer cells.

Another potential drug target for LINC02291 is its role in the regulation of cellular metabolism. LINC02291 has been shown to be involved in the metabolism of several nutrients, including glucose and oxygen, which are critical for the survival and growth of cells. This suggests that LINC02291 may be a potential drug target for diseases that are characterized by disruptions in cellular metabolism, such as cancer and neurodegenerative diseases.

In addition to its potential as a drug target or biomarker, LINC02291 has also been shown to have potential as a diagnostic tool. Studies have shown that LINC02291 is expressed in the brains of patients with Alzheimer's disease, and that its levels are correlated with the severity of the disease. This suggests that LINC02291 may be a potential diagnostic tool for the diagnosis of Alzheimer's disease.

In conclusion, LINC02291 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. Its association with the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders, as well as its potential as a diagnostic tool, make it an important area of research for the development of new treatments and therapies. Further studies are needed to fully understand the role of LINC02291 in disease and to determine its potential as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2291

The "LINC02291 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02291 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets